Harold E. Glass

Early Life:
Professor Harold Glass was born in California and after graduating high school he attended the London School of Economics. Following graduation he then went on to University of North Carolina to receive his PhD.
Career:
In 1990 Professor Glass founded DataEdge, pioneering the area of drug development cost benchmarking by creating PICAS and CROCAS while at DataEdge. Then in 2001 Professor Glass founded TTC, llc along with Holly Squires. TTC's main competitors inclue Medidata Solutions and ClearTrial. This allowed him to remain at the head of cost benchmarking innovation by introducing more progressive cost benchmarking tools.
Academia:
In addition to founding DataEdge and TTC Professor Glass is also a professor at two different universities. He is a research professor at University of the Sciences. He started teaching at the university in 2001 where he lectures in the Department of Health Policy and Public Health as well as the Department of Pharmaceutical and Healthcare Business. His area of research at the university include international business along with clinical trials. Lastly, he is a Visiting Professor in the Department of Political Economy at King's College London.
Publications:
Through out his life as a businessman and scholar Professor Glass has also written an abundant amount of publications and newsletters. You can find his works published in journals such as Drug Information Journal, Applied Clinical Trials, International Journal of Pharmaceutical and Healthcare Marketing, Pharmaceutical Medicine, and Contemporary Clinical Trials
Peer Reviewed Publications:
[http://ttc-llc.com/LinkClick.aspx?fileticket=M3tDZZdurF8%3d&tabid66&mid392 Latin American Physician's Attitudes Toward Participation in Clinical Trials. Glass H. & Glass J. Pharmaceutical Medicine 25 (2): pp 87-94 2011]
[http://ttc-llc.com/Portals/0/images/PDFLibrary/CRO%20Selection%20&%20Management_Glass_Beaudry.pdf CRO Selection & Management. Glass H. & Beaudry D. Applied Clinical Trials pp48-54 April 2009]
[http://ttc-llc.com/Portals/0/images/PDFLibrary/Managing%20Clinical%20Grant%20Costs_Glass%20&%20Hollander.pdf Managing Clinical Grant Costs. Glass H. & Hollander K. Contemporary Clinical Trials February 2009]
[http://ttc-llc.com/Portals/0/images/PDFLibrary/investigator%20dissatisfaction%20with%20the%20conduct%20of%20clinical%20trials%20-%20Glass.pdf Investigator Dissatisfaction with the Conduct of Clinical Trials. Glass H. The Monitor August 2009]
[http://ttc-llc.com/Portals/0/images/PDFLibrary/Pressure%20Points%20on%20Pharmaceutical%20Industry%20Executives_What%20Lies%20Ahead_Glass%20&%20Poli.pdf Pressure Points on Industry Executives: What Lies Ahead? Glass H. Poli L. International Journal of Pharmaceutical and Healthcare Marketing pp 74-83 2009]
[http://ttc-llc.com.dnnmax.com/Portals/0/images/PDFLibrary/The%20profile%20of%20the%20one-time%201572%20investigator%20Glass%20.pdf The Profile of the One-Time 1572 Investigator. Glass H. Contemporary Clinical Trials pp 34-39 May 2009]
[http://www.diahome.org/DIAHome/resources/content.aspx?typeeopdf&file%2fproductfiles%2f8357%2fdiaj_26507.pdf The Importance of Medical Innovation in an Investigator's Decision to Take Part in Clinical Trials. Glass H. Drug Information Journal pp 537-543 March 2008]
[http://ttc-llc.com/Portals/0/images/PDFLibrary/Key%20Factors%20in%20CRO%20Selection_Glass%20&%20Beaudry.pdf Key Factors in CRO Selection. Glass H. Beaudry D. Applied Clinical Trials April 2008]
[http://pubget.com/paper/pgtmp_fbf7d030d5e67ff5324a17a9ecc4819c# Profiles of Phase 4 Investigators and Subsequent Prescribing of the Study Drug. Glass H. Dalton D. Journal of Pharmaceutical Marketing and Management June 2007]
[http://ttc-llc.com/Portals/0/images/PDFLibrary/The%20Marketplace%20for%20Clinical%20Grants,%20Glass.pdf The Marketplace for Clinical Grants. Glass H. Monitor pp 69-74 October 2005]
[http://ttc-llc.com/Portals/0/images/PDFLibrary/The%20Dual%20Role%20of%20Company%20Prescribing%20Loyalty%20in%20New%20Drug%20Launches_Glass_Poli.pdf The Dual Role of Company Prescribing Loyalty in new Drug Launches. Glass H. Poli L. Journal of Pharmaceutical Marketing and Management July 2004]
[http://ttc-llc.com/Portals/0/images/PDFLibrary/Demographic,%20Practice%20and%20Prescribing%20Characteristics%20of%20Physicians%20Who%20Are%20Early%20Adopters%20of%20New%20Drugs_Glass_Rosenthal.pdf Demographics, Practices, and Prescribing Characteristics of Physicians Who are Early Adopters of New Drugs. Glass H. & Rosenthal B. Pharmacy & Therapeutics November 2004]
[http://ttc-llc.com/LinkClick.aspx?fileticket=HEXkAk7uQB0%3d&tabid66&mid392 Do Clinical Grant Payment Practices in Phase 3 Clinical Trials Influence Subsequent Clinical Investigator Prescribing Behavior? Glass H. Disease Management pp77-87 November 2004]
[http://ttc-llc.com/Portals/0/images/PDFLibrary/Physician%20Participation%20in%20Market%20Support%20Clinical%20Studies%20and%20Subsequent%20Prescribing%20Behavior_Glass.pdf Physician Participation in Market Support Clinical Studies and Subsequent Prescribing Behavior. Glass H. Journal of Pharmaceutical Marketing & Management pp 3-16 May 2003]
Industry Publications:
[http://ttc-llc.com/Portals/0/images/PDFLibrary/Controlling%20Costs%20of%20Clinical%20Trials%20in%20Oncology%20Request-Pharma_FOCUS_Issue3.pdf Controlling Costs of Clinical Trials in Oncology. Glass H & Poli L. FOCUS pp 22-27 February 2011]
[http://ttc-llc.com/Portals/0/images/PDFLibrary/InvestigatorInsights%20CRO%20or%20Sponsor%20Preferenc%20-%20%20feature%20Dec10.pdf Investigator Insights; CRO or Sponsor Preferences? Glass H. Scrip Clinical Research pp 16-17 December 2010]
[http://ttc-llc.com/Portals/0/images/PDFLibrary/What%20bothers%20clinical%20investigators_Glass.pdf What Bothers Clinical Investigators. Glass H. Good Clinical Practice Journal pp 21-23 July 2009]
[http://www.contemporaryclinicaltrials.com/article/S1551-7144%2809%2900012-3/abstract Managing Clinical Grant Costs. Glass H. Hollander K. Contemporary Clinical Trials October 2009]
[http://ttc-llc.com/Portals/0/images/PDFLibrary/Connecting%20the%20Dots%20Glass%20%20Poli.pdf Connecting the Dots. Glass H. Poli L. Pharmaceutical Executive January 2007]
[http://ttc-llc.com/Portals/0/images/PDFLibrary/Outlook%20for%20Outsourcing,%20Glass.pdf Outlook for Outsourcing. Glass H. Good Clinical Practice Journal pp 21-24 November 2007]
[http://ttc-llc.com/Portals/0/images/PDFLibrary/The%20CRO%20Crop,%20Glass%20&%20Beaudry.pdf The CRO Crop. Glass H. & Beaudry D. Inside Outsourcing November 2007]
[http://ttc-llc.com/Portals/0/images/PDFLibrary/Clinical%20Grants_What%20is%20a%20Fair%20Market%20Value%20Harold%20Glass.pdf Clinical Grants: What is a Fair Market Value? Glass H. Good Clinical Practice Journal pp 23-25 August 2006]
[http://ttc-llc.com/Portals/0/images/PDFLibrary/Researchers%20as%20Marketers,%20Dr.%20Harold%20E.%20Glass.pdf Researchers as Marketers. Glass H. Successful Clinical Trials Management pp 16-19 June 2004]

Main Menu

See Also

Main Menu